Companies: 10,795·Total market cap: $144.5T
CytoMed Therapeutics Limited

CytoMed Therapeutics Limited

GDTCNASDAQHealthcare● Active
$1.15
$-0.14(-10.85%)
Market Cap$13607760
P/E Ratio—
52W High$3.68
52W Low$0.68
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

CytoMed Therapeutics Limited (GDTC) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001873093 · GDTC · NASDAQ · as of Jun 9, 2026

Filing snapshot

121
Total Filings
6-K
Latest Form
2026-06-03
Most Recent
2023
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001873093 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2026-03-31
Fiscal Year End
Mar 31, 2026
Accession No.
0001493152-26-013813
Primary Document
form20-f.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001873093 · Accession 0001493152-26-013813

Latest Key Filings

6-KQuarterly Report
6-K
2026-06-03
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
6-KCurrent Report (Foreign Issuer)
6-K
2026-06-03
View
3Initial Statement of Beneficial Ownership
3
2026-05-26
View
3Initial Statement of Beneficial Ownership
3
2026-05-15
View
3Initial Statement of Beneficial Ownership
3
2026-05-15
View
3Initial Statement of Beneficial Ownership
3
2026-05-15
View
3Initial Statement of Beneficial Ownership
3
2026-05-15
View
3Initial Statement of Beneficial Ownership
3
2026-05-15
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-15
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-11
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-14
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-03-31
View
20-FAnnual Report (Foreign Issuer)
20-F
2026-03-31
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-01-28
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-01-13
View
6-KCurrent Report (Foreign Issuer)
6-K
2025-12-08
View
Showing 1–15 of 115 filingsForm 4 / 144 hidden· 121 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001873093  |  Exchange: NASDAQ · Healthcare

CytoMed Therapeutics Limited (NASDAQ: GDTC) has submitted 121 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2023. As a Healthcare sector company with CIK 0001873093, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is CytoMed Therapeutics Limited's most comprehensive regulatory disclosure. The most recent CytoMed Therapeutics Limited 10-K was filed on 2026-03-31 for fiscal year ending 2026. Historical GDTC 10-K annual reports are available from 2021 through 2026.

Investors researching CytoMed Therapeutics Limited SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
NRXS SEC Filings →LSTA SEC Filings →XCUR SEC Filings →NRSN SEC Filings →PASG SEC Filings →ENLV SEC Filings →NCNA SEC Filings →SONN SEC Filings →
→ GDTC Financials→ GDTC Earnings→ GDTC Insider Trades

Frequently Asked Questions

GDTC SEC Filings · 8 questions

CytoMed Therapeutics Limited (GDTC) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 121 filings and access original documents at no cost. CytoMed Therapeutics Limited's CIK is 0001873093.

GDTC SEC filingsCytoMed Therapeutics Limited SEC documentsfind GDTC 10-K